Product
Campath®
Licensee
Genzyme Corporation
Indication
B-cell chronic lymphocytic leukaemia (B-CLL), multiple sclerosis (MS)
Phase
Approved – B-CLL
Phase III – MS
Description
Monoclonal antibody targeting the CD52 antigen.
Further Information
Campath® (alemtuzumab) is approved as a single agent for the treatment of B-cell chronic lymphocytic leukaemia (B-CLL). It binds to the CD52 antigen, which is present on the surface of B and T lymphocytes and other cells. After binding to the CD52 antigen present on the surface of leukaemic cells, it destroys them.
In a completed Phase II trial comparing Campath® with Rebif® (interferon beta-1a) for the treatment of MS, Campath® was found to have a significant treatment effect that lasted for the three-year duration of the study. Patients taking Campath® experienced a 73% reduction in the risk for relapse and at least a 70% reduction in the risk for progression of clinically significant disability compared with patients treated with Rebif®.
Two Phase III trials are underway. One is comparing Campath® to Rebif® as a first-line therapy for patients with relapsing-remitting MS, and the second is also enrolling patients who have continued to experience relapse episodes while on currently available disease modifying therapies.
Return to Pipeline